Oculis Holding AG (OCS) Change in Accured Expenses (2022 - 2026)
Quarterly Change in Accured Expenses rose 6.43% to $23.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $23.5 million through Mar 2026, up 6.43% year-over-year, with the annual reading at $25.0 million for FY2025, 20.26% up from the prior year.
Oculis Holding AG's Change in Accured Expenses history spans 5 years, with the latest figure at $23.5 million for Q1 2026.
- Change in Accured Expenses came in at $23.5 million for Q1 2026, down from $25.0 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $25.0 million in Q4 2025 to a low of -$4.8 million in Q1 2024.
- The 5-year median for Change in Accured Expenses is $17.0 million (2024), against an average of $15.5 million.
- Year-over-year, Change in Accured Expenses dropped 19.36% in 2023 and then soared 564.48% in 2025.
- Oculis Holding AG's Change in Accured Expenses stood at $8.3 million in 2022, then dropped by 19.36% to $6.7 million in 2023, then surged by 209.8% to $20.8 million in 2024, then increased by 20.26% to $25.0 million in 2025, then fell by 5.89% to $23.5 million in 2026.
- Per Business Quant, the three most recent readings for OCS's Change in Accured Expenses are $23.5 million (Q1 2026), $25.0 million (Q4 2025), and $24.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 107.70 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Oculis Holding AG | 24.51 Bn | 24.21 Bn | - | 23.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.51 Mn |
| Mar 31, 2026 | 23.51 Mn |
| Dec 31, 2025 | 24.98 Mn |
| Dec 31, 2025 | 24.98 Mn |
| Sep 30, 2025 | 24.93 Mn |
| Sep 30, 2025 | 24.93 Mn |
| Jun 30, 2025 | 24.06 Mn |
| Jun 30, 2025 | 24.06 Mn |
| Mar 31, 2025 | 22.09 Mn |
| Mar 31, 2025 | 22.09 Mn |
| Dec 31, 2024 | 20.77 Mn |
| Dec 31, 2024 | 20.77 Mn |
| Sep 30, 2024 | 16.97 Mn |
| Sep 30, 2024 | 16.97 Mn |
| Jun 30, 2024 | 14.11 Mn |
| Jun 30, 2024 | 14.11 Mn |
| Mar 31, 2024 | -4.76 Mn |
| Mar 31, 2024 | -4.76 Mn |
| Dec 31, 2023 | 6.71 Mn |
| Dec 31, 2023 | 6.71 Mn |
| Sep 30, 2023 | 9.83 Mn |
| Sep 30, 2023 | 9.83 Mn |
| Jun 30, 2023 | 9.35 Mn |
| Jun 30, 2023 | 9.35 Mn |
| Dec 31, 2022 | 8.32 Mn |
| Dec 31, 2022 | 8.32 Mn |